translation agency

Reuters New Media
Europe recommends approving Schering-Plough drug

October 18, 2002
NEW YORK, Oct 18 (Reuters) - Schering-Plough Corp. SGP.N said an advisory panel to Europe's drug regulators recommended approving the company's Caelyx drug as a stand-alone therapy for breast cancer patients who have an increased risk of heart attacks.

The Committee for Proprietary Medicinal Products, the main advisory body to the European Commission, which is charged with approving or rejecting the drug, issued a "positive opinion" recommending approval of Caelyx, Schering-Plough said.

Caelyx is already marketed in the 15-nation European Union for the treatment of advanced ovarian cancer in women who have failed the standard platinum-based therapy. The drug is also sold as a treatment for an AIDS-related skin disorder known as Kaposi's sarcoma.

Schering-Plough, which is based in Kenilworth, New Jersey, has exclusive non-U.S. licensing rights to the drug, except in Japan and Israel, through a distribution agreement with a subsidiary of Johnson & Johnson JNJ.N .

The drug is marketed in the United States under the brand name Doxil by Johnson & Johnson.